Trial Profile

A Multicentre, Randomised, Double-blind, Controlled, Phase IIIb Study to Assess the Efficacy and Safety of Rivaroxaban 10mg od Versus Enoxaparin 4000 UI for VTE PROphylaxis in NOn Major Orthopaedic Surgery

Status: Discontinued

Phase of Trial: Phase III

Latest Information Update: 11 Sep 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Rivaroxaban (Primary) ; Enoxaparin sodium
Indications Deep vein thrombosis; Pulmonary embolism; Venous thromboembolism
Focus Therapeutic Use
Acronyms PRONOMOS

11 Sep 2024 This trial has been completed in Hungary.
29 Mar 2020 Results published in the New England Journal of Medicine
29 Mar 2020 According to a Bayer media release, data were published in The New England Journal of Medicine and presented during a virtual session of the American College of Cardiology 69th Annual Scientific Session together with World Congress of Cardiology (ACC.20/WCC Virtual) .

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com